McKesson
About: McKesson Corp is one of three leading pharmaceutical wholesalers in the us engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the us pharmaceutical wholesale industry. Outside the us market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Employees: 51,000
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
60% more call options, than puts
Call options by funds: $980M | Put options by funds: $613M
4.71% less ownership
Funds ownership: 88.05% [Q2] → 83.34% (-4.71%) [Q3]
6% less funds holding
Funds holding: 1,604 [Q2] → 1,513 (-91) [Q3]
21% less capital invested
Capital invested by funds: $66.6B [Q2] → $53B (-$13.7B) [Q3]
22% less repeat investments, than reductions
Existing positions increased: 505 | Existing positions reduced: 649
27% less funds holding in top 10
Funds holding in top 10: 45 [Q2] → 33 (-12) [Q3]
46% less first-time investments, than exits
New positions opened: 107 | Existing positions closed: 198
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
Morgan Stanley Erin Wright 48% 1-year accuracy 11 / 23 met price target | 11%upside $642 | Overweight Maintained | 17 Dec 2024 |
Wells Fargo Stephen Baxter 20% 1-year accuracy 8 / 40 met price target | 11%upside $641 | Equal-Weight Maintained | 13 Dec 2024 |
Citigroup Daniel Grosslight 41% 1-year accuracy 7 / 17 met price target | 23%upside $713 | Buy Maintained | 13 Nov 2024 |
Evercore ISI Group Elizabeth Anderson 34% 1-year accuracy 11 / 32 met price target | 17%upside $680 | Outperform Maintained | 7 Nov 2024 |
Baird Eric Coldwell 32% 1-year accuracy 11 / 34 met price target | 19%upside $688 | Outperform Upgraded | 7 Nov 2024 |
Financial journalist opinion
Based on 24 articles about MCK published over the past 30 days